EFFECTIVENESS OF 3% TOPICAL IMIQUIMOD IN OFF-LABEL USE FOR ORAL FLORIDA PAPILLOMATOSIS: A CASE REPORT

D06 – Antibiotics and chemotherapeutics for dermatological use 3PC-011

L. Rendón de Lope[1], P. Ruiz Huertas[2], C. Donoso Rengifo[1], M. Murillo Izquierdo[1], C. Castillo Martín[1], J. Cordero Ramos[1,] M.D. Alvarado Fernández[1], M. Fernández González[1], M.L. Moya Martín[1].
[1]Hospital Universitario Virgen Macarena, Pharmacy, Seville, Spain.
[2]Hospital Universitario Virgen Macarena, Oral and Maxilofacial Surgery, Seville, Spain.

OBJECTIVES

Imiquimod: immunomodulator, with antitumor activity, indicated for the treatment of genital and perianal warts.

Description of a clinical case of **Oral Florida Papillomatosis** (PFO) treated with topical **imiquimod** at 3% in a 74-years-old woman with numerous recurrences after failure to surgical treatment.

2008
PFO diagnosis

2010
Removal Papilloma and CO2 laser vaporization

2011
Biopsy: verrucous carcinoma and hyperplasia

2011, 2017 and 2018
Excision and skin grafting

2018
Start of treatment with topical IMIQUIMOD 3%

MATERIAL AND METHODS

Elaboration: using an oral adhesive excipient to prolong the permanence of the drug in oral mucosa and reduce adverse effects on healthy skin areas.

Posology: 1 application at night, 3 days per week, during 16 weeks. Each application assumes a dose of approx. 0.01 g of imiquimod (340 mg of preparation).

RESULTS AND DISCUSSION



Start of treatment



+ 2 weeks



+ 6 weeks



+ 8 weeks



+ 11 weeks

+ 16 weeks: the papillomatous lesions of the floor of the mouth and lingual tip had disappeared, and a small lesion remained in the lower lip.

- Its preparation with **oral adhesive excipient** and its nocturnal application favor the permanence of the drug in the affected area.
- Hyaluronic acid gel was added in order to reduce the adverse effects of imiquimod on healthy perilesional mucosa.

CONCLUSION

The clinical evolution of the patient suggests that the oral application of imiquimod 3% is safe and well tolerated, being effective in the treatment of PFO and thus avoiding repeated surgical interventions.

JUNTA DE ANDALUCIA
Servicio Andaluz de Salud
CONSEJERÍA DE SALUD Y FAMILIAS
eahp european association of hospital pharmacists
http://www.eahp.eu/24-3PC-011
making the difference in medication
Hospital Universitario Virgen Macarena